Nanomedicine in Central Nervous System Injury and Repair

Erscheinungsjahr 2017
ISBN: 978-0-12-812381-2
Verlag: William Andrew Publishing

Buch, Englisch, 182 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 450 g

Nanomedicine in Central Nervous System Injury and Repair (IRN), Volume 137, the latest release in the International Review of Neurobiology series presents comprehensive chapters that cover a broad range of topics, including, but not limited to, how Diabetes exacerbates methamphetamine induced blood-brain barrier breakdown, edema formation, oxidative stress and myelin damage, and how Focal blast brain injury induces rapid edema formation, blood-brain barrier breakdown and intensive cellular damage. In addition, the Neuroprotective effects of a multimodal drug cerebrolysin are explored, as is how Nanowired cerebrolysin potentiates neuroprotective effects of histamine H3 receptor inverse agonist and antagonist with partial H4 agonist in Alzheimer's Disease.

This series reviews current knowledge and understanding on how to repair the damaged spinal cord and brain with nanomedicine, detailing new therapeutic advances and providing a starting point for researchers and practitioners entering the field.

Autoren/Hrsg.

Weitere Mitwirkende

Jenner, Peter

Sharma, Aruna

Fachgebiete

• Interdisziplinäres Wissenschaften Wissenschaften Interdisziplinär Neurowissenschaften, Kognitionswissenschaft
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft
• Naturwissenschaften Biowissenschaften Biowissenschaften Neurobiologie, Verhaltensbiologie

Inhaltsverzeichnis

1. Current Strategies for the Delivery of Therapeutic Proteins and Enzymes to Treat Brain Disorders J.T. Duskey, D. Belletti, F. Pederzoli, M.A. Vandelli, F. Forni, B. Ruozi, G. Tosi1 2. Impact of inflammation on the blood-neural barrier and blood-nerve interface: from review to therapeutic preview Stephen D. Skaper 3. Intravenous administration of Functionalized Magnetic Iron Oxide Nanoparticles does not induce CNS injury in the rat. Influence of spinal cord trauma and Cerebrolysin treatment Preeti K Menon, Aruna Sharma, José Vicente Lafuente, Dafin F Muresanu, Zoraida P. Aguilar, Y. Andrew Wang, Ranjana Patnaik, Herbert Mössler, Hari S Sharma 4. Histaminergic Receptors Modulate Spinal cord Injury induced neuronal Nitric Oxide Synthase Upregulation and Cord Pathology. New Roles of Nanowired drug delivery for Neuroprotection Hari Shanker Sharma, Ranjana Patnaik,  Dafin F Muresanu, José Vicente Lafuente, Asya Ozkizilcik, Z Ryan Tian, Ala Nozari, Aruna Sharma 5. Nanoformulation, a useful therapeutic strategy for improving neuroprotection and the neurorestorative potential in experimental models of Parkinson's Disease Lafuente JV1,  Requejo C, Carrasco A, Pomposo I, Bengoetxea H 6. Novel treatment strategies using TiO2 nanowired delivery of Histaminergic drugs and antibodies to tau with cerebrolysin for superior Neuroprotection in the pathophysiology of Alzheimer's disease Aruna Sharma, Preeti K Menon, Ranjana Patnaik, Dafin F Muresanu, José Vicente Lafuente, Z Ryan Tian, Asya Ozkizilcik, Rudy J Castellani, Herbert Mössler

Über Autor(innen)

Jenner, Peter
Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson's disease. He has spent the major part of his career at King's College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King's College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.

Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson's disease patient-carer groups across the UK.

Sharma, Aruna
Aruna Sharma, MD is currently Secretary of Research at Uppsala University Hospital, Uppsala University, Sweden. She obtained her Bachelor of Science in 1971 and trained in Indian Medicine up to 1977 and engaged in medical research from 1978 to 1986 in India on hyperthermia induced brain dysfunction in the lab of Hari Sharma and Prasanta Kumar Dey under University Grants Commission and Indian Council of Medical Research

Her main interest is now focused on Indian Medicinal drugs and their effects on the Central Nervous System Function, toxicology, neurorepair and neuroprotection. She is also investigating neurotoxicological profiles of many Ayurvedic traditional drugs with special reference to those containing metal oxide or metal ashes.